Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...

AbbVie ABBV stock has risen 30.7% in the past six months compared with an increase of 8.9% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart ...

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their ...

AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for ...

Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street ...

AbbVie ABBV has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. Image Source: ...